Last reviewed · How we verify
AS902330
At a glance
| Generic name | AS902330 |
|---|---|
| Also known as | rhFGF 18, Recombinant human fibroblast growth factor 18, Sprifermin |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee (PHASE2)
- A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee (PHASE2)
- Sprifermin (AS902330) in Cartilage Injury Repair (CIR) (PHASE2)
- Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement (PHASE1)
- A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AS902330 CI brief — competitive landscape report
- AS902330 updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI